ZFYVE27 Gene SPG33 Genetic Test
Components
- Price: 4400.0 AED
Sample Condition
Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery
3 to 4 Weeks
Method
NGS Technology
Test Type
Neurological Disorders
Doctor
Neurologist
Test Department
Genetics
Pre Test Information
Clinical History of Patient who is going for ZFYVE27 Gene SPG33 NGS Genetic DNA Test
A Genetic Counselling session to draw a pedigree chart of family members affected with ZFYVE27 Gene SPG33
Test Details
The ZFYVE27 gene is associated with a rare neurological disorder called hereditary spastic paraplegia type 33 (SPG33). This disorder is characterized by progressive muscle stiffness and weakness in the lower limbs, leading to difficulty walking and often requiring the use of a wheelchair.
NGS (Next-Generation Sequencing) genetic testing is a type of genetic test that uses advanced sequencing technology to analyze multiple genes simultaneously. In the case of SPG33, NGS genetic testing can be used to identify mutations or variations in the ZFYVE27 gene that may be causing the disorder. This can help with the diagnosis of SPG33 and provide information about the underlying genetic cause of the condition.
NGS genetic testing for SPG33 typically involves obtaining a DNA sample, usually through a blood sample or a cheek swab. The DNA is then sequenced using NGS technology to analyze the ZFYVE27 gene and other relevant genes associated with hereditary spastic paraplegia.
The results of the test can help confirm a diagnosis, provide information about the genetic cause of the disorder, and may also have implications for family members who may be at risk of inheriting the condition.
It is important to note that genetic testing for SPG33 is typically done in specialized genetic testing laboratories and requires a healthcare provider’s referral. Genetic counseling is often recommended before and after testing to discuss the implications of the test results and provide support and guidance to individuals and families affected by SPG33.
| Test Name | ZFYVE27 Gene SPG33 Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card o |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Neurological Disorders |
| Doctor | Neurologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for ZFYVE27 Gene SPG33 NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with ZFYVE27 Gene SPG33 |
| Test Details | The ZFYVE27 gene is associated with a rare neurological disorder called hereditary spastic paraplegia type 33 (SPG33). This disorder is characterized by progressive muscle stiffness and weakness in the lower limbs, leading to difficulty walking and often requiring the use of a wheelchair. NGS (Next-Generation Sequencing) genetic testing is a type of genetic test that uses advanced sequencing technology to analyze multiple genes simultaneously. In the case of SPG33, NGS genetic testing can be used to identify mutations or variations in the ZFYVE27 gene that may be causing the disorder. This can help with the diagnosis of SPG33 and provide information about the underlying genetic cause of the condition. NGS genetic testing for SPG33 typically involves obtaining a DNA sample, usually through a blood sample or a cheek swab. The DNA is then sequenced using NGS technology to analyze the ZFYVE27 gene and other relevant genes associated with hereditary spastic paraplegia. The results of the test can help confirm a diagnosis, provide information about the genetic cause of the disorder, and may also have implications for family members who may be at risk of inheriting the condition. It is important to note that genetic testing for SPG33 is typically done in specialized genetic testing laboratories and requires a healthcare provider’s referral. Genetic counseling is often recommended before and after testing to discuss the implications of the test results and provide support and guidance to individuals and families affected by SPG33. |
